ClinicalTrials.gg
CompletedNCT01649804Updated Nov 4, 2016Results posted

A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
105th of 110
12 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
61st of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 105th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 61st registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis. Participants who have completed the core study WA19926 are eligible to participate. Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, >/=18 years of age who have completed the core study WA19926 and according to the investigator may benefit from RoActemra/Actemra treatment
  • No current or recent adverse event or laboratory finding preventing the use of the study drug dose at baseline
  • Receiving treatment on an outpatient basis

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant
  • Participants who have prematurely withdrawn from the core study WA19926 for any reason
  • Treatment with any drug since the last administration of the study drug in the core study WA19926
  • Treatment with an anti-tumor necrosis (TNF), anti-interleukin 1 agent or T-cell costimulation modulator since the last administration of the study drug in the core study WA19926
  • Immunization with live/attenuated vaccine since the last administration of the study drug in the core study WA19926
  • Diagnosis since the last WA19926 visit of rheumatic disease or inflammatory joint disease other than rheumatoid arthritis
  • Abnormal laboratory values
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    RoActemra/Actemra single arm

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg intravenously every 4 weeks for 104 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

    An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. Adverse Events of Special Interest for this study were: Serious and/or medically significant infections; myocardial infarction/Acute coronary syndrome; Gastrointestinal perforation; Malignancies; Anaphylaxis/hypersensitivity reactions; Demyelinating disorders; Stroke and Serious and/or medically significant bleeding and hepatic events.

    Time frame: End of Study (Week 104 or early withdrawal)

Secondary outcomes

  1. Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR)

    The DAS28 (ESR) score is a measure of the participant's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), erythrocyte sedimentation rate (ESR) and general health status. The DAS28-ESR scale ranges from 0 to 10, where higher scores represent higher disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity, DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.

    Time frame: Screening and End of Study (Week 104 or early withdrawal)

  2. Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Simplified Disease Activity Index (SDAI)

    The SDAI was defined as the numerical sum of 5 outcome parameters: tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity on a 100 millimeter (mm) Visual analogue scale (VAS) (VAS; 0 = no disease activity and 100 = worst disease activity) and level of C-reactive protein (CRP) (milligram per deciliter \[mg/dl\], normal \< 1 mg/dl). SDAI total score = 0-86 where a higher score reflects worsening disease. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

    Time frame: Screening and End of Study (Week 104 or early withdrawal)

  3. Number of Participants With Decreased, Unchanged, and Increased Tender Joint Count (TJC)

    Tender joint count was performed by a skilled assessor, evaluating 68 joints for tenderness.

    Time frame: Week 12 and Week 104

  4. Number of Participants With Decreased, Unchanged, and Increased Swollen Joint Count (SJC)

    Swollen joint count was performed by a skilled assessor, evaluating 66 joints for swelling.

    Time frame: Week 12 and Week 104

  5. Time to Rheumatoid Arthritis (RA) Flare

    RA flare was defined as any worsening of the participant's disease activity that in the opinion of the Investigator required treatment intensification beyond supportive therapy which included restarting of the study drug treatment. Time to RA flare was defined as the period of drug-free remission until documentation of RA flare. Drug-free remission was defined as clinical remission (based on DAS28-ESR \< 2.6 and /or SDAI ≤ 3.3) for two consecutive assessment visits, followed by discontinuation of tocilizumab, at the Investigator's discretion, at the second assessment visit.

    Time frame: End of Study (Week 104 or early withdrawal)

  6. Number of Participants With Decreased, Unchanged, and Increased Participants Global Assessment of Disease Activity

    The participant global assessment of disease activity was measured using a 100 mm VAS ranging from 0=very good to 100=very bad.

    Time frame: Week 12 and Week 104

  7. Number of Participants With Decreased, Unchanged, and Increased Participant Global Assessment of Pain

    A participant's overall assessment of pain on a VAS was assessed with a question concerning the amount of pain due to arthritis. Pain was assessed on a 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm).

    Time frame: Week 12 and Week 104

  8. Health Assessment Questionnaire Disability Index (HAQ-DI)

    The Health Assessment Questionnaire Disability Index (HAQ-DI) is a participant-completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores divided by the number of domains answered. Total possible scores range from 0 to 3, where 0=least difficulty, and 3=extreme difficulty.

    Time frame: End of Study (Week 104 or early withdrawal)

07

Results

Posted Sep 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started12
Completed4
Not completed8
Withdrew: Administrative/other8

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. Adverse Events of Special Interest for this study were: Serious and/or medically significant infections; myocardial infarction/Acute coronary syndrome; Gastrointestinal perforation; Malignancies; Anaphylaxis/hypersensitivity reactions; Demyelinating disorders; Stroke and Serious and/or medically significant bleeding and hepatic events.

Time frame:
End of Study (Week 104 or early withdrawal)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
percentage of participantsTocilizumab
AEs75
SAEs0
AESI0
SecondaryNumber of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR)

The DAS28 (ESR) score is a measure of the participant's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), erythrocyte sedimentation rate (ESR) and general health status. The DAS28-ESR scale ranges from 0 to 10, where higher scores represent higher disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity, DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.

Time frame:
Screening and End of Study (Week 104 or early withdrawal)
Reported as:
Number · participants
Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR)
participantsTocilizumab
Remission (Baseline)5
Low Disease Activity (Baseline)1
Moderate Disease Activity (Baseline)4
High Disease Activity (Baseline)2
Remission (End of Study)10
Low Disease Activity (End of Study)1
Moderate Disease Activity (End of Study)0
High Disease Activity (End of Study)1
SecondaryNumber of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Simplified Disease Activity Index (SDAI)

The SDAI was defined as the numerical sum of 5 outcome parameters: tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity on a 100 millimeter (mm) Visual analogue scale (VAS) (VAS; 0 = no disease activity and 100 = worst disease activity) and level of C-reactive protein (CRP) (milligram per deciliter \[mg/dl\], normal \< 1 mg/dl). SDAI total score = 0-86 where a higher score reflects worsening disease. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

Time frame:
Screening and End of Study (Week 104 or early withdrawal)
Reported as:
Number · participants
Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Simplified Disease Activity Index (SDAI)
participantsTocilizumab
Remission (Baseline)0
Low Disease Activity (Baseline)6
Moderate Disease Activity (Baseline)3
High Disease Activity (Baseline)3
Remission (End of Study)3
Low Disease Activity (End of Study)7
Moderate Disease Activity (End of Study)1
High Disease Activity (End of Study)1
SecondaryNumber of Participants With Decreased, Unchanged, and Increased Tender Joint Count (TJC)

Tender joint count was performed by a skilled assessor, evaluating 68 joints for tenderness.

Time frame:
Week 12 and Week 104
Reported as:
Number · participants
Number of Participants With Decreased, Unchanged, and Increased Tender Joint Count (TJC)
participantsTocilizumab
Decreased (Week 12; n=11)5
Unchanged (Week 12; n=11)4
Increased (Week 12;n=11)2
Decreased (Week 104;n=4)2
Unchanged (Week 104;n=4)2
Increased (Week 104;n=4)0
SecondaryNumber of Participants With Decreased, Unchanged, and Increased Swollen Joint Count (SJC)

Swollen joint count was performed by a skilled assessor, evaluating 66 joints for swelling.

Time frame:
Week 12 and Week 104
Reported as:
Number · participants
Number of Participants With Decreased, Unchanged, and Increased Swollen Joint Count (SJC)
participantsTocilizumab
Decreased (Week 12; n=11)3
Unchanged (Week 12; n=11)7
Increased (Week 12;n=11)1
Decreased (Week 104;n=4)2
Unchanged (Week 104;n=4)2
Increased (Week 104;n=4)0
SecondaryTime to Rheumatoid Arthritis (RA) Flare

RA flare was defined as any worsening of the participant's disease activity that in the opinion of the Investigator required treatment intensification beyond supportive therapy which included restarting of the study drug treatment. Time to RA flare was defined as the period of drug-free remission until documentation of RA flare. Drug-free remission was defined as clinical remission (based on DAS28-ESR \< 2.6 and /or SDAI ≤ 3.3) for two consecutive assessment visits, followed by discontinuation of tocilizumab, at the Investigator's discretion, at the second assessment visit.

Time frame:
End of Study (Week 104 or early withdrawal)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Decreased, Unchanged, and Increased Participants Global Assessment of Disease Activity

The participant global assessment of disease activity was measured using a 100 mm VAS ranging from 0=very good to 100=very bad.

Time frame:
Week 12 and Week 104
Reported as:
Number · participants
Number of Participants With Decreased, Unchanged, and Increased Participants Global Assessment of Disease Activity
participantsTocilizumab
Decreased (Week 12; n=11)6
Unchanged (Week 12; n=11)0
Increased (Week 12;n=11)5
Decreased (Week 104;n=4)2
Unchanged (Week 104;n=4)0
Increased (Week 104;n=4)2
SecondaryNumber of Participants With Decreased, Unchanged, and Increased Participant Global Assessment of Pain

A participant's overall assessment of pain on a VAS was assessed with a question concerning the amount of pain due to arthritis. Pain was assessed on a 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm).

Time frame:
Week 12 and Week 104
Reported as:
Number · participants
Number of Participants With Decreased, Unchanged, and Increased Participant Global Assessment of Pain
participantsTocilizumab
Decreased (Week 12; n=11)7
Unchanged (Week 12; n=11)4
Increased (Week 12;n=11)0
Decreased (Week 104;n=4)2
Unchanged (Week 104;n=4)0
Increased (Week 104;n=4)2
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI)

The Health Assessment Questionnaire Disability Index (HAQ-DI) is a participant-completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores divided by the number of domains answered. Total possible scores range from 0 to 3, where 0=least difficulty, and 3=extreme difficulty.

Time frame:
End of Study (Week 104 or early withdrawal)
Reported as:
Mean · units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI)
units on a scaleTocilizumab
Health Assessment Questionnaire Disability Index (HAQ-DI)1.18 ± 0.953

Adverse events

Collected over End of Study (Week 104 or early withdrawal). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—0/12 (0%)9/12 (75%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTocilizumab
NasopharyngitisInfections and infestations3/12
DiarrhoeaGastrointestinal disorders2/12
DermatitisSkin and subcutaneous tissue disorders2/12
RanulaGastrointestinal disorders1/12
CystitisInfections and infestations1/12
InfluenzaInfections and infestations1/12
Otitis externaInfections and infestations1/12
Otitis mediaInfections and infestations1/12
Respiratory tract infectionInfections and infestations1/12
Arthropod biteInjury, poisoning and procedural complications1/12

Baseline characteristics

Analysis population included all the enrolled participants in the study.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean51.25 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female8
Male4
08

Study locations

3 sites
  • Budapest, 1027, Hungary
  • Debrecen, 4032, Hungary
  • Eger, 3300, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2012
First posted
Jul 25, 2012
Start
Jul 2012
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Sep 22, 2016
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01649804
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Jul 2012
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Sep 22, 2016
Last update
Nov 4, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion